Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Capecitabine
Drug: Doxorubicin
Drug: Ixabepilone
Drug: Docetaxel
Drug: Paclitaxel
Drug: Brivanib alaninate

First Posted Date: 2008-11-26

Last Posted Date: 2015-07-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 111

Registration Number: NCT00798252

Locations: 🇨🇦
Local Institution, Toronto, Ontario, Canada
🇺🇸
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

Phase 1

Completed

Conditions: Advanced Melanoma

Interventions: Drug: Ipilimumab
Drug: Dacarbazine
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2008-11-24

Last Posted Date: 2014-01-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 72

Registration Number: NCT00796991

Locations: 🇺🇸
The Angeles Clinic & Research Inst., Los Angeles, California, United States
🇺🇸
H Lee Moffit Cancer Cnt And Res Inst, Tampa, Florida, United States
🇺🇸
Blumenthal Cancer Center, Carolinas Medical Center, Charlotte, North Carolina, United States

and more 1 locations

Chemotherapeutic Agents in Brain/Breast

Completed

Conditions: Metastatic Cancer
Breast Cancer

First Posted Date: 2008-11-21

Last Posted Date: 2013-08-02

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 10

Registration Number: NCT00795678

Locations: 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: cediranib maleate
Other: placebo
Drug: paclitaxel

First Posted Date: 2008-11-21

Last Posted Date: 2023-08-22

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 306

Registration Number: NCT00795340

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

and more 16 locations

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors
Metastatic Solid Tumors

Interventions: Drug: BMS-754807
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2008-11-19

Last Posted Date: 2012-07-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 21

Registration Number: NCT00793897

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

Phase 1

Completed

Conditions: HER-2 Positive Breast Cancer
Metastatic Breast Cancer

Interventions: Drug: IV LBH589
Drug: Oral LBH589
Drug: trastuzumab
Drug: paclitaxel

First Posted Date: 2008-11-11

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT00788931

Locations: 🇳🇱
Novartis Investigative Site, Amsterdam, Netherlands

Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients

Phase 2

Conditions: Adrenocortical Carcinoma

Interventions: Drug: Sorafenib
Drug: Paclitaxel

First Posted Date: 2008-11-06

Last Posted Date: 2009-02-24

Lead Sponsor: University of Turin, Italy

Target Recruit Count: 30

Registration Number: NCT00786110

Locations: 🇮🇹
Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
🇮🇹
Azienda Ospedaliera di Padova, Padova, Italy
🇮🇹
Ist. Clin.Humanitas, Rozzano, Italy

and more 2 locations

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Phase 3

Completed

Conditions: Estrogen Receptor Negative
HER2/Neu Positive
Progesterone Receptor Positive
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Stage IIIC Breast Cancer AJCC v6
Estrogen Receptor Positive
HER2/Neu Negative
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Ixabepilone
Drug: Nab-paclitaxel
Drug: Paclitaxel
Other: Questionnaire Administration

First Posted Date: 2008-11-05

Last Posted Date: 2022-10-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 799

Registration Number: NCT00785291

Locations: 🇺🇸
Altru Cancer Center, Grand Forks, North Dakota, United States
🇺🇸
Saint Vincent Frontier Cancer Center, Billings, Montana, United States
🇺🇸
Mercy Hospital Springfield, Springfield, Missouri, United States

and more 694 locations

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Phase 2

Active, not recruiting

Conditions: Neoplasm Metastasis

Interventions: Drug: Docetaxel
Drug: Paclitaxel
Drug: Pertuzumab
Drug: Trastuzumab
Drug: Trastuzumab Emtansine
Drug: Atezolizumab

First Posted Date: 2008-10-29

Last Posted Date: 2025-01-03

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 720

Registration Number: NCT00781612

Locations: 🇺🇸
Can Care Assoc Med Group Inc, Redondo Beach, California, United States
🇺🇸
Univ of Calif, San Francisco, San Francisco, California, United States
🇺🇸
UCLA Oncology Office, Santa Monica, California, United States

and more 177 locations

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Epirubicine
Drug: Aromatase Inhibitor
Drug: Bevacizumab
Drug: 5-Fluorouracil (5FU)
Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Docetaxel

First Posted Date: 2008-10-16

Last Posted Date: 2023-01-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 150

Registration Number: NCT00773695

Locations: 🇳🇴
Ullevael Sykehus; Dept of Oncology, Oslo, Norway
🇳🇴
The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, Norway
🇳🇴
St. Olavs Hospital; Kreftavdelingen, Trondheim, Norway

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy